PROGRAMME OVERVIEW

PROVISIONAL - Last update: 20 October 2026

Date	Time *(CET)*	Event	Location
Tuesday 17 November	13:30-17:00	*Eurosurveillance* pre-conference workshop: How to improve your chances to get published in scholarly journals	**ECDC premises** Gustav III:s Boulevard, 40 169 73 Stockholm
	15:30-17:00	ECDC pre-conference workshop: Episomer: social media threat detection	**Waterfront Congress Centre** Nils Erikson Plan 4 111 64 Stockholm
	16:00-18:00	ECDC pre-conference workshop: Misinformation Olympics	
Wednesday 18 November	08.00-21.00	**Conference Day 1**	**Waterfront Congress Centre** Nils Erikson Plan 4 111 64 Stockholm
Thursday 19 November	08.00-20.35	**Conference Day 2**	
Friday 20 November	08.00-15.45	**Conference Day 3**	

NOTE: Pre-conference workshops have limited capacity and require separate registration. Please visit escaide.eu for more information.

CONFERENCE PROGRAMME – DAY 1

PROVISIONAL - Last update: 20 October 2026

CET time zone	**DAY 1** – *Wednesday 18 November 2026*		
08.00-09.00	**Registration and welcome coffee**		
09.00-09.30	**Opening ceremony** A1		
09.30-10.30	**Plenary session A:** Crises and challenges shaping the landscape of public health: how far we've come *Chaired by the ESCAIDE Scientific Committee members Alicia Barrasa (UKHSA/EAN, United Kingdom) and Piotr Kramarz (ECDC, Sweden)* *Speaker: Shingai Machingaidze (Coalition for Epidemic Preparedness Innovations/International Pandemic Preparedness Secretariat, United Kingdom)* A1		
10.30-11.00	Coffee break M1		
11.00-12.30	**Fireside session 1:** Respiratory viruses: evidence to practice A1	**Fireside session 2:** Food- and water-borne diseases A2	11.00-12.20 **Thematic session 1:** Towards interoperable One Health Data Space, *organised by European Partnership on One Health AMR (EUP OHAMR)* *Moderated by Linda van Gaalen (ZonMw, Netherlands)* *Speakers: Elina Drakvik (Sitra, Finland), Christian Giske (ECDC), Katharina Schaufler (Helmholtz Institute for One Health, Germany), Alice Aldora (World Organisation for Animal Health, France), Nichola Hawkins (Niab, UK)* A4
12.30-14.15	Lunch break M1 + Balcony		12.45-14.05 **Thematic session 2:** European Union Reference Laboratories (EURLs) in outbreak response and beyond, *organised by ECDC* *Moderated by Maximilian Riess (ECDC) and Andreas Hoefer (ECDC)* *Speakers: Klara Sondén (Public Health Agency of Sweden), Camilla Wiuff Coia (SSI, Denmark), Camille Jacqueline (Hospices Civils de Lyon, France)* A2 12.40-14.05 **EAN General Assembly** A4
14.15-15.45	**Fireside session 3:** Anti-microbial resistance A1	**Fireside session 4:** Outbreaks of food- and water-borne diseases A2	**Fireside session 5:** Surveillance and investigation A4
15.55-16.55	**Poster tour 1:** Outbreak investigations of food-borne diseases | **Poster tour 2:** One Health | **Poster tour 3:** Surveillance of vaccine-preventable diseases | **Poster tour 4:** Surveillance, outbreaks and high-risk populations | **Poster tour 5:** Burden of respiratory diseases | **Poster tour 6:** Communication and behavioural aspects | **Poster tour 7:** SDG-targeted infections | **Poster tour 8:** Healthcare-associated infections M1	**Thematic session 3:** From data to pandemic decisions in EU, *organised by the Norwegian Institute of Public Health (NIPH) and BE READY Partnership* *Moderated by Thomas Hoffman (ECDC)* *Speakers: Bjørn G Iversen (Norwegian Institute of Public Health), Tonje Sande Laird (Norwegian Institute of Public Health), Evelyn Depoortere (DG RTD)* A2	

16.55-17.15	Coffee break M1 + Balcony
17.15-18.30	**Plenary session B:** The science behind EU health security *Chaired by the ESCAIDE Scientific Committee members Bruno Ciancio (ECDC, Sweden) and Miłosz Parczewski (Pomeranian Medical University, Poland)* *Speakers: Gianfranco Spiteri (ECDC, Sweden), Helen Brown (Safinea, Ireland), and Magdalena Rosińska (National Public Health Institute, Poland)* A1
19.00-21.00	**Networking event**, venue TBC

NOTE: This is a provisional programme. Details will be added and updated as the programme develops and sessions are confirmed. Timings and content may change. A final version will be published closer to the conference dates.

CONFERENCE PROGRAMME – DAY 2

PROVISIONAL - Last update: 20 October 2026

CET time zone	**DAY 2** – *Thursday 19 November 2026*		
08.00-09.00	**Registration and welcome coffee**		
09.00-10.30	**Plenary session C:** Communication to (re)build trust in science *Chaired by the ESCAIDE Scientific Committee members Tyra Grove Krause (Statens Serum Institut, Denmark) and Koen Blot (Sciensano, Belgium)* *Speakers: Anders Hviid (Statens Serum Institut, Denmark), Steven van Gucht (Sciensano, Belgium), and Tina D Purnat (Harvard Chan School of public health, United States)* A1		
10.30-11.00	Coffee break M1		
11.00-12.30	**Fireside session 6:** Healthcare-associated infections A1	**Fireside session 7:** Vaccine-preventable diseases: from evidence to practice A2	**Fireside session 8:** Social determinants and actions for public health A4
12.30-14.15	Lunch break M1 + Balcony	12.40-14.10 ***Eurosurveillance*** **lunch seminar:** Three decades of serving infectious disease prevention and control in Europe *Moderated by Shingai Machingaidze (Coalition for Epidemic Preparedness Innovations/IPPS, UK)* *Speakers: Kevin Fenton (NHS London, UK), Ana Marušić (University of Split School of Medicine, Croatia), Roberto Croci (SSI, Denmark)* C1+C2+C3 12.40-13.10 **Refresh and recharge session** *Facilitated by Irina Ljungqvist (ECDC)* Bar area floor 5	
14.15-15.45	**Fireside session 9:** SDG 3.3 - targeted diseases A1	**Fireside session 10:** Respiratory viruses: surveillance and response A2	**Fireside session 11:** Late breakers (1) A4
15.55-16.55	**Poster tour 9:** One Health and food and water-borne diseases | **Poster tour 10:** Preparedness and response | **Poster tour 11:** Surveillance and prevention of respiratory viruses | **Poster tour 12:** Burden and prevention of vaccine-preventable diseases | **Poster tour 13:** Data systems and surveillance | **Poster tour 14:** Surveillance and outbreak investigations of AMR | **Poster tour 15:** Artificial intelligence in public health | **Poster tour 16:** Late breakers (1) M1	**Thematic session 4:** Advancing action towards SDG 3.3 among migrant populations in Europe: scaling up evidence based best practices, *organised by ECDC* *Moderated by Charlotte Deogan (ECDC)* *Speakers: Ana Requena (Barcelona Institute of Global Health, Spain), Abimbola Ajomale (Noaks Ark Mosaik, Sweden), Margarida Torres (National Health Services Portugal), Gonçalo Bento (National Health Services Portugal)* A2	
16.55-17.15	Coffee break M1 + Balcony		
17.15-18.45	**Plenary session D:** Learning from data: integrated surveillance of respiratory infections *Chaired by the ESCAIDE Scientific Committee members Angeliki Melidou (ECDC, Sweden) and Nadine Zeitlmann (Robert Koch Institute, Germany)* *Speakers: Nick Bundle (ECDC, Sweden), John Brownstein (Harvard Medical School/Boston Children's Hospital, United States), Trine Hessevik Paulsen (FHI, Norway), and Ron Fouchier (Erasmus University Medical Centre, Netherlands)*		

	A1
19.00-20.30	**BarCamp** Bar area floor 5

NOTE: This is a provisional programme. Details will be added and updated as the programme develops and sessions are confirmed. Timings and content may change. A final version will be published closer to the conference dates

CONFERENCE PROGRAMME – DAY 3

PROVISIONAL - Last update: 20 October 2026

CET time zone	**DAY 3** – *Friday 20 November 2026*		
08.00-09.00	**Registration and welcome coffee**		
09.00-10.30	**Plenary session E:** Modelling for better public health decisions *Chaired by the ESCAIDE Scientific Committee members Jose Canevari (ECDC, Sweden) and Hana Orlíková (National Institute of Public Health, Czech Republic)* *Speakers: Moritz Kraemer (University of Oxford, United Kingdom), Sheetal Silal (Modelling and Simulation Hub, Africa (MASHA), University of Cape Town, South Africa), and Julian Savulescu (National University of Singapore)* A1		
10.30-11.00	Coffee break M1		
11.00-12.30	**Fireside session 12:** Quantitative methods A1	**Fireside session 13:** Late breakers (2) A2	11.00-12.20 **Thematic session 5:** Can Public Health work without the "public"?, *organised by ECDC* *Moderated by Barbara Albiger (ECDC) and Cristina da Cruz (ECDC)* *Speakers: Ulrika Björkstén (Public & Science Sweden), Sébastien Français (Luxembourg Health Directorate), Stacey Vickers (European Commission), Jörgen Lööf (ElectriCITY, Sweden)* A4
12.30-14.15	Lunch break M1 + Balcony		12.40-14.10 **Career compass:** Where can a career in epidemiology and microbiology in public health take you?, *organised by EAN* *Moderated by Natalie Fischer (Institut Pasteur Paris, France), Joaquin Baruch (WHO, Germany)* *Speakers: Amrish Baidjoe (MSF, Luxembourg), Ines Steffens (ECDC), Veronik Hutse (Sciensano, Belgium), Gianfranco Spiteri (ECDC)* A4 12.45-14.05 **Simulation exercise**: Bridging the gap between disciplines in crisis: interdisciplinary scientific advice for policy, *organised by Pandemic & Disaster Preparedness Center (PDPC)* *Moderated by Jeannette de Boer (PDPC, Netherlands)* *Facilitators: Femke Overbosch (PDPC, Netherlands), Aloïs Kessener (PDPC, Netherlands)* C4
14.15-15.15	**Poster tour 17:** Surveillance of food- and water-borne diseases | **Poster tour 18:** Surveillance of COVID-19 and influenza | **Poster tour 19:** Vaccine-preventable diseases: evidence to practice | **Poster tour 20:** Vector-borne diseases | **Poster tour 21:** Quantitative methods | **Poster tour 22:** Social determinants of infectious diseases | **Poster tour 23:** Evidence to practice | **Poster tour 24:** Late breakers (2) M1		**Thematic session 6:** Cross-sectoral response to C**B**RN threats, *organised by ECDC* *Moderated by Agoritsa Baka (ECDC)* *Speakers: Arménio José Louro Liceia (Polícia de Segurança Pública, Portugal), Paul William Riley (ECDC), João Simões (Europol), Tomoya Saito (Japan Institute for Health Security)* A1
15.25-15.45	**Closing ceremony** A1		

NOTE: This is a provisional programme. Details will be added and updated as the programme develops and sessions are confirmed. Timings and content may change. A final version will be published closer to the conference dates.

FIRESIDE SESSIONS PROGRAMME *PROVISIONAL: last update 20 October 2026*

CET time zone

DAY 1 - *18 November*

11.00-12.30

Fireside session 1

Respiratory viruses: evidence to practice

a. Developing a respiratory swabbing tool in FluSurvey to support pandemic preparedness in England, **Hannah Wolmuth-Gordon**

b. Nirsevimab effectiveness in preventing RSV hospitalisations in children under 24 months: second season post-national immunisation implementation in Portugal (2025–2026), **Vânia Gaio**

c. Disentangling school-related and community transmission contributions to SARS-CoV-2 cases in secondary school students across pandemic phases, **Clarize de Korne**

d. Insights from implementing active surveillance for avian and swine influenza virus infections in humans in Denmark, 10 September 2024 to 7 May 2026, **Gudrun Witteveen-Freidl**

e. Impact of autumn 2023 and 2024 COVID-19 vaccination in preventing COVID-19 related hospitalisations and deaths in individuals aged ≥65 years from seven EU/EEA countries: a multicentre electronic health records-based study (VEBIS-EHR), **Baltazar NUNES**

f. Governance of Scientific Advice for Policymaking during COVID-19: Lessons from Sweden and Switzerland, **Fereshteh Kazemipour**

Fireside session 2

Food- and water-borne diseases

a. Setting norovirus activity level thresholds using the moving epidemic method, England, 2015-2025, **David Elliott**

b. Are Non-Contemporaneous Controls a Valid Source of Controls in Foodborne Outbreak Investigations?, **Rebecca Howarth**

c. Comparative epidemiology and seasonality of Cryptosporidium hominis and Cryptosporidium parvum in Wales, 2022 to 2024**, Craig Hogg**

d. Genomic epidemiology of clinical Listeria monocytogenes clusters in Norway, 2016–2025, **Kristian Alfsnes**

e. Vibrio and Shewanella infections in Denmark: a six-year nationwide retrospective epidemiological overview, 2020–2025, **Kristyna Faksova**

f. Ecological determinants and projections of cholera in South Kivu province, Democratic Republic of Congo, 2021–2028., **Ousmaila Bianpambe**

14.15-15.45

Fireside session 3

Antimicrobial resistance

a. Implementation Gaps in Antimicrobial Stewardship in Pakistan: Implications for Surveillance and Public Health Practice, **Ghania Nadeem**

b. European multi-country outbreak of NDM-5-producing Enterobacter hormaechei ST1344, March 2025–April 2026, **Núria Balanza**

c. From data silos to federated One Health antimicrobial surveillance: early implementation results for Estonia and Romania, **Laura-Madalina Lixandru**

d. Outbreak investigation and molecular characterization of community associated methicillin resistant Staphylococcus aureus in a secondary school in Thuringia, Germany, 2025, **Sophia Wirth**

e. Genomic virulence scores and clinical outcomes among carbapenem-resistant Klebsiella pneumoniae infections in Germany, 2023–2025, **Simon Brinkwirth**

f. From Fragmentation to Integration: Strengthening One Health AMR Surveillance Governance in Europe, **Carmela Pagano**

Fireside session 4

Outbreaks of food- and water-borne diseases

a. No iron curtain for HAV: Transnational Hepatitis A outbreak shifting gears in Austria in 2025, **Miriam Van den Nest**

b. Salmonella Bochum outbreak in children caused by chocolate hazelnut spread, Germany 2026, **Hanna Buck**

c. Assessment of post-exposure vaccination campaign in control of hepatitis A outbreak in a socially vulnerable community, Czech Republic, 2025, **Eva Patrasová**

d. A foodborne hepatitis A outbreak at a manufacturing plant in Taiwan, January–February 2026, **Po-Han Huang**

e. Investigation of a cereulide-contaminated infant formula outbreak: Belgian evidence from human case confirmation, **Géraldine De Muylder**

f. Shiga toxin-producing Escherichia coli O45:H2 infections in close contacts and shedding duration during a large outbreak in Germany, 2025, **Bettina Rosner**

Fireside session 5

Surveillance and investigation

a. Guillain-Barré syndrome cases triggered by infections: a case-control study, Denmark, 1 January 2010 to 20 April 2026, **Roberto Croci**

b. Spread of multidrug-resistant and extensively-drug resistant Shigella strains among gay, bisexual and other men who have sex with men in Europe, **Cecilia Jernberg**

c. Comparison of three Haemophilus influenzae b serotyping assays used in the Netherlands and other European countries reveals variability in assay sensitivity, **Olivia Luise Gern**

d. Environmental detection of Sabin-like poliovirus type 3 in Barcelona, Spain, 2025: investigation of asymptomatic excretors and public health response, **Maria Dolores Fernandez Garcia**

e. Invasive Pneumococcal Disease in Western Lisbon, 2020-2025: Surveillance Data and Public Health Implications, **Inês Félix Mendes**

f. Complementary Use of Wastewater Surveillance Indicators to Determine the Onset of Influenza and Respiratory Syncytial Virus Waves in Germany; 2023-2026, **Susan Abunijela**

FIRESIDE SESSIONS PROGRAMME *PROVISIONAL: last update 20 October 2026*

CET time zone

DAY 2 - *19 November*

11.00-12.30

Fireside session 6

Healthcare-associated infections

a. Outbreak management: The Strategy for Addressing Future Epidemics in Nursing Homes (SAFE-NH) study, **Eveline Coemans**

b. Sink-drain replacement to control a carbapenemase-producing Klebsiella pneumoniae outbreak in a surgical ward, Gran Canaria, Spain, 2024–2026, **Pablo Pérez Ruiz**

c. A protracted outbreak of VIM carbapenemase-producing Pseudomonas aeruginosa in a Welsh hospital, **Hannah Jones**

d. Targeted metagenomic analysis of causes of influenza-like and respiratory illness in healthcare workers over winter, United Kingdom, 2023-2024, **Lucy Findlater**

e. Multicountry surveillance data on neonatal healthcare-associated infections from the NeoIPC Surveillance Network, **Gizem Karadağ**

f. Time-to-Antibiotics in Sepsis and Septic Shock: A Systematic Review and Meta-Analysis Accounting for Severity-of-Illness Adjustment, **Selina Ehrenzeller**

Fireside session 7

Vaccine-preventable diseases: from evidence to practice

a. An evidence-based update of recommendations for meningococcal vaccination in Germany: Introducing quadrivalent vaccination in adolescence and discontinuing meningococcal C vaccination in childhood, **Vanessa Piechotta**

b. Epidemiological impact assessment of the second winter of RSV immunisation of infants with nirsevimab, Ireland 2025/2026**, Laura Kayaert**

c. Association between influenza vaccination and severe outcomes in adults aged ≥65 years hospitalised with laboratory-confirmed influenza: a retrospective cohort study in Europe, 2015/16–2024/25, **Angela MC Rose**

d. Reducing antibiotic eligibility from 21 to 14 days after symptom onset for cases and contacts of pertussis in England did not increase household clustering, **Eleanor Clarke**

e. Vaccine effectiveness of the influenza vaccine administered alone or concomitantly with COVID-19 vaccine against influenza A subtype hospitalisation among older adults: results from a multi-centre study, Europe, 2023/24 and 2024/25 influenza seasons, **Angela MC Rose**

f. Statistical modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, **Liliana Antunes**

Fireside session 8

Social determinants and actions for public health

a. An ethical roadmap for local wastewater surveillance deployment, **Maarten de Jong**

b. Addressing the data gaps: A survey of Clostridioides difficile infection practices in England, September - December 2025, **Amreet Battu**

c. From surveillance to action: One Health use of Highly pathogenic avian influenza (HPAI) data for decision making and risk communication in Norway, 2024-2026, **Tora Ziesler**

d. Association between socioeconomic deprivation and pertussis incidence in HSE Dublin and Midlands, 2024, **Christopher Murray**

e. Upsurge in congenital syphilis in the EU/EEA: time to scale up public health responses, **Otilia Mårdh**

f. Parental refusal of HPV vaccination in Morocco: prevalence and associated factors from a multicentre cross-sectional study, **Chaymae Zerrouk**

14.15-15.45

Fireside session 9

SDG 3.3 - targeted diseases

a. Breaking barriers to hepatitis C diagnosis among previously unreached people who inject drugs in sub-saharan Africa: A multi-country peer-driven network intervention increased HCV Diagnosis Coverage Twofold, **Chimere Nwagbo**

b. Viral Hepatitis and HIV Among People Who Use Drugs in a German Prison: Disease Prevalence and Access to Care in a Mixed-Methods Study (2025), **Antonia Genath**

c. Evaluating Türkiye's Progress Toward the WHO End TB Strategy: A Time-Series Forecasting Study of Incidence and Mortality, Ali Kılınç

d. Beyond Coverage: Non-use of Available Insecticide-Treated Nets and Its Implications for Malaria Risk Among Children Under Five in Zambia, **Azibadighi Walter**

e. Integrating epidemiological and entomological data to assess the risk of autochthonous dengue transmission in Spain, **Lidia Redondo Bravo**

f. Unmasking Cutaneous Leishmaniasis Outbreak in an Endemic Village, Southeast Türkiye, 2025–2026, **Hacer Demirkose**

Fireside session 10

Respiratory viruses: surveillance and response

a. Effectiveness and early impact of maternal RSV vaccination in Denmark, 1 November 2025 – 30 April 2026, **Ida Rask Moustsen-Helms**

b. COVID-19 vaccine effectiveness in the primary care setting among older adults in Europe in 2025/26, **Esther Kissling**

c. Early vaccine effectiveness estimates of the 2025 autumn LP.8.1-adapted COVID-19 vaccine dose against hospitalisation and death in six EU/EEA countries: VEBIS-EHR network, October 2025 to January 2026, **James Humphreys**

d. Characteristics of influenza-like illness in the community during the 2025-2026 influenza A(H3N2) subclade K dominant season, **Becki Green**

e. Vaccine effectiveness against seasonal influenza A(H1N1)pdm09 and highly drifted influenza A(H3N2) subclade K at primary care level in Europe in 2025/26, **Héloïse Lucaccioni**

f. Rapid One Health response to a zoonotic HPAI A(H5N1) outbreak involving poultry, domestic cats and occupational exposure of veterinary staff and first responders in Germany, February 2026, **Aparna Dressler**

	Fireside session 11 **Late breakers (1)** a. Evidence for mixed zoonotic and person-to-person transmission of Andes hantavirus outbreak during an international expedition cruise, April-June 2026, **Oda van den Berg** b. Outbreak of Legionnaires' disease associated with a misting system in a restaurant, Chambéry, France, 2026, **Emmanuelle Vaissière** c. Observational environmental study of possible transmission routes during an outbreak of Andes virus on the M/V Hondius expedition cruise ship, **Janko van Beek** d. International carbapenem-resistant Acinetobacter baumannii outbreak in burn intensive care units with ongoing transmission in Germany, 2026, **Sophia Melhem** e. Large outbreak of autochthonous West Nile virus infection in humans in the Netherlands: preliminary investigation of cases from the Utrecht province, August – September 2026, **Annelein Kuiperbak**	

CET time zone

DAY 3 - *20 November*

11.00-12.30	Fireside session 12 **Quantitative methods** a. Estimating the Presence and Abundance of Aedes albopictus in Europe Using Neural Networks, **Indaco Biazzo** b. Reuse of unstructured hospital-based electronic health record data to enhance automated surveillance of severe acute respiratory infections in the Netherlands., **Carsten van Rossum** c. Progressive intensification of respiratory syncytial virus epidemics in India (2022–2025): transmission dynamics, forecasting, and implications for immunoprophylaxis timing, **Sachin Sudesh Desh** d. Population-level effectiveness of long-acting monoclonal antibodies and maternal vaccination against RSV-associated hospitalisation in infants: a modelling study across 28 European countries, **Elisa Viola** e. Climate-driven leptospirosis in Greece: predictive modeling for early warning, **Zacharoula Bogogiannidou** f. Mpox vaccination among MSM in the EU/EEA: Estimating the uptake and modelling the impact of future campaigns, **Bastian Franklin**	Fireside session 13 **Late breakers (2)** a. Lower-than-expected rotavirus vaccine effectiveness in Dutch children? Preliminary findings from a test negative case–control study, **Marije Bootsma** b. Environmental drivers of transmission in an ongoing human tularaemia outbreak in Brittany, France, 2026, **Lorenzo Arena** c. Increasing delays across sequential tuberculosis regimen modifications and potential utility of upfront nanopore targeted next-generation sequencing in Kyrgyzstan, **Aizat Kulzhabaeva** d. Municipal-scale dengue early warning in Colombia: prospective model performance amid the confirmed 2026 national outbreak, **Hernan Silva** e. Investigation and population vaccination response for a multi-settingoutbreak of Hepatitis A in South Wales, December 2025 to September 2026., **Joshua Matizanadzo**

POSTER TOURS PROGRAMME

PROVISIONAL: last update 20 October 2026

DAY 1 - *18 November: 15.55-16.55 (CET time zone)*

Poster tour 1

Outbreak investigations of food-borne diseases

a. Traditional Household Slaughtering Practices as Determinants of Brucellosis Risk in High Burden Areas, Armenia, 2025, **Armine Chopikyan**

b. Brucellar epididymo-orchitis in an endemic setting: clinical features, management and outcomes from a single-centre study, **Sevak Mirabyan**

c. Tip of the Iceberg Salad: Investigation of a Salmonella Typhimurium Outbreak in Denmark, November- December 2025, **Cheyenne Gumbs**

d. Outbreak of Salmonella Enteritidis Associated with Egg Based Dishes in a Restaurant in Malta, November 2025, **Gabrielle Grixti Galdes**

e. Foodborne outbreaks associated with large-volume catering: Insights from multiple Clostridium perfringens investigations in Wales, December 2024 - December 2025, **Grace King**

f. Salmonella Typhimurium (monophasic) Outbreak Investigation Utilising Loyalty Card Purchase Data, United Kingdom, January to March 2026, **Katie Bolam**

g. Integrating Whole-Genome Sequencing (WGS) to Reinforce Traditional Epidemiological Investigation of a Foodborne Salmonella Outbreak, Moldova, 2025, **Anna Punga**

Poster tour 2

One Health

a. Operationalizing One Health in Emergency Preparedness and Response: Lessons Learned from Marburg Virus Disease Outbreak Response in Ethiopia, Rwanda, and Tanzania, **Tedros Fikru Teshome**

b. Avian Pathogenic Escherichia coli in Humans and Poultry in the Czech Republic, **Veronika Illíková**

c. Antimicrobial resistance in unprocessed food from conventional versus antibiotic-free and organic production systems: a systematic review and meta-analysis, **Giulia Bonanno**

d. Meteorological exposures associated with reported Legionnaires' disease incidence in Greece: a 17-year time-series analysis, **Christina Morphaki**

e. Linking food animal reservoirs to human campylobacteriosis through integrated One Health genomic surveillance in Ireland, 2017–2025, **Pedro Pinto**

f. Shared resistance plasmids in third-generation cephalosporin-resistant Escherichia coli from livestock, meat and humans in Spain, **Carlos Serna**

g. Farm-animal exposure and OXA-48-like carbapenemase-producing Enterobacterales carriage among Arab patients in northern Israel: a case-control study, **Ronza Najjar**

Poster tour 3

Surveillance of vaccine-preventable diseases

a. Maternal pertussis vaccination coverage and sociodemographic and maternal factors associated with non-uptake in Sweden: preliminary results from a nationwide cohort study, **Kévin Lasmi**

b. Spatiotemporal dynamics of measles resurgence in the EU/EEA: spatially independent outbreaks driven by national vaccination gaps, 1999–2024, **Dimitrios Kontogiannis**

c. Evaluating Measles Surveillance toward Elimination in North Rhine-Westphalia, Germany, 2024 and 2025, **Connor Moran**

d. Novel serology assay reveals large unascertained community burden of pertussis in children in North Wales, UK during the 2023-2024 epidemic., **Jennifer Howard**

e. Analysis of global mpox outbreak dynamics during the 2024-2026 Public Health Emergency, **Florence Gyembuzie Wongnaah**

f. Re-emergence of diphtheria in Germany: Differences between imported and autochthonous cases with C. diphtheriae, 2017–2025, **Lena Schneider**

g. Rapid escalation and sustained transmission of measles in an under-vaccinated community, Enfield, London, 2026, **Erjola Hani**

Poster tour 4

Surveillance, outbreaks and high-risk populations

a. Evaluation of the Cerebrospinal Meningitis surveillance system: Lessons from Sokoto State, Nigeria, **Juliet Namugenyi**

b. Outbreaks in asylum seeker accommodations in Germany, 2015-2025, **Inessa Markus**

c. Closing the Diagnostic Gap: Determinants of Timely Mpox Diagnosis and Genomic Sequencing under the 7-1-7 Framework in the Democratic Republic of the Congo, 2022–2025, **Pride Tanyi Bobga**

d. Spatial heterogeneity in RSV-SARI incidence in children at the city level: sociodemographic and epidemiological determinants of urban hotspots and coldspots, Lyon, France, 2012–2025., **Jean-Sebastien Casalegno**

e. Unrelated or linked? Integrating whole genome sequencing into epidemiological investigation to unravel a measles outbreak in Utrecht, the Netherlands, 2024, **Liza Coyer**

f. Predominance of antimicrobial-resistant serotype V Streptococcus agalactiae among colonised pregnant women in Poland, **Maksymilian Kempa**

g. Evaluation of Acute Encephalitis Syndrome (AES) Surveillance under the National Digital Disease Surveillance Platform, Assam, India, 2025, **Ashwini Yadav**

Poster tour 5

Burden of respiratory diseases

a. Describing age-specific respiratory syncytial virus incidence and establishing an epidemiological baseline in Croatia (2017–2025), **Andela Vrbica**

b. Increased risk of human metapneumovirus (hMPV) infection during the first two years of life among children born <28 weeks preterm in Lyon, France, 2012–2025, **Laura Rojas-Lopez**

c. Drivers, impact and costs of respiratory illness on the national health service (NHS) workforce over winter 2025/26 in the United Kingdom, **Sarah Foulkes**

d. COvid-19 among HEalth caRE professionals in the Nordic CountriEs (COHERENCE II), **Débora Gräf**

e. Differential Severity of Acute Respiratory Infection Outbreaks by Pathogens in Nursing Homes, **Gladys Lee**

f. Epidemiology of Respiratory Syncytial Virus and risk factors for severe outcomes among children <2 years hospitalised with respiratory infection in Skopje, Republic of North Macedonia, October 2025–April 2026, **Iris Finci**

g. Population-level burden of rhinovirus, influenza, and SARS-CoV-2 among adults: A multi-season analysis in the Netherlands, 2022–2025, **Gesa Carstens**

Poster tour 6

Communication and behavioural aspects

a. Awareness, attitude and practices related to brucellosis among female pastoralists of Pakistan: A one health perspective, **Olivier Sparagano**

b. Triangulated digital surveillance during a suspected cholera alert in Poland., **Maja Romanowska**

c. Comparison of vaccination determinants across seven diseases in Germany: a cross-sectional study, **Paula Dau**

d. High Awareness, Low Action: Gaps in Cervical Cancer Screening and HPV Vaccination Among Women Living with HIV in North Central Nigeria, **Oluwaseun Ojomo**

e. Measles outbreak in Antwerp, Belgium 2025: targeted response in an under-vaccinated community and lessons from an after-action review, **Aaron Devos**

f. Knowledge, attitudes and practice towards HPV vaccination among students, Kazakhstan, 2023, **Arystan Balmagambetov**

Poster tour 7

SDG-targeted infections

a. A pre- and post-intervention analysis of the TB surveillance system in Spain, 2018-2024, **Allegra Priya Chatterjee**

b. Performance Evaluation of Computer-Aided Detection for Triage of Chest X-Rays in Tuberculosis Screening in Ukraine, **Ludmila Kasatkina**

c. Hepatocellular carcinoma mortality following hepatitis B and C infection in Slovenia, 2016–2022: national datasets linkage study to monitor progress towards hepatitis B and C elimination, **Eva Leban**

d. Genomic epidemiology and insights on the resistance profile of Treponema pallidum in Portugal, **Diogo Ramos**

e. Increasing trends in reported gonorrhoea incidence in young adults in Slovenia, 2005-2024, **Matija Mozetič**

f. Optimising the PEP to PrEP Transition: Policy Relevant Evidence from a Structured Prevention Pathway in a Lisbon Hospital, **Bárbara Cardoso**

g. Tuberculosis among people already registered as contacts: linking tuberculosis centre, hospital and notification records in northern Portugal, 2024–2026, **Pedro Sebastiao**

Poster tour 8

Healthcare-associated infections

a. Temporal patterns of severe Clostridioides difficile infections in Germany, 2016–2025, **Lukas Herrmann**

b. High background noise masks transmission: whole genome sequencing as a key tool for outbreak assessment of Pseudomonas aeruginosa in a high-incidence setting, **Julia Kuhn**

c. Emergence of NDM-1 and OXA-48 producing Klebsiella pneumoniae ST395 circulating within and between hospitals with links to Ukraine, Germany, 2023-2025, **Claudia Ruscher**

d. The association between comorbidities and recurrent urinary tract infections in Dutch long-term care residents: a longitudinal cohort study, **Charlotte de Bruijn - Onstwedder**

e. Trends in surgical site infection incidence in Piedmont, Italy, 2015–2024: findings from a regional surveillance programme, **Ilaria Long**

f. Compliance with minimum requirements for infection prevention and control programs across healthcare facilities in Nigeria, 2024, **Paul Wekunda**

g. Escalating Antimicrobial Resistance and Healthcare-Associated Infections in Greek ICUs: A Ten-Year Longitudinal Surveillance Study, **Eleni Jelastopulu**

POSTER TOURS PROGRAMME

PROVISIONAL: last update 20 October 2026

DAY 2 - *19 November: 15.55-16.55 (CET time zone)*

Poster tour 9

One Health and food- and water-borne diseases

a. Environmental detection of Campylobacter spp. in soil during a childcare-associated gastroenteritis cluster, **Pedro Mendes Reis**

b. Increasing incidence of human tularaemia despite stable epidemiological patterns, Baden-Wuerttemberg, Germany, 2012–2025, **Sabrina Nothdurfter**

c. Cluster of human leptospirosis associated with environmental exposure in southern Spain, 2025/2026., **Blanca Lopez-Villalba**

d. The Unveiling: Human Paragonimiasis concealed behind TB-culture samples in a National Reference Laboratory, Metro Manila, Philippines, June-October 2025, **Mary Coleen Rivera**

e. Water Infrastructure Proximity and Informal Settlements as Drivers of Cholera: A Geospatial Analysis of the 2022–2023 Outbreak in Bebnine, Lebanon, **Hawraa Sweidan**

f. Cholera outbreak investigation in an urban setting: transmission dynamics and response gaps in Nairobi County, Kenya, March–April 2025, **Habiba Mohamed**

g. Unraveling Legionellosis Dynamics in the Lazio Region: Effects of Individual, Territorial and Meteorological determinants, **Martina Spaziante**

Poster tour 10

Preparedness and response

a. Developing an evaluation framework for Epidemic Intelligence from Open Source (EIOS): a qualitative analysis of stakeholder priorities, **Imme Roewer de Porto**

b. Childhood immune imprinting and seasonal influenza-driven boosting of cross-reactive avian influenza A antibody landscapes in adults: evidence from a German population-based longitudinal cohort study, 2020-2024, **Yaw Awuku-Larbi**

c. Pooled testing for SARS-CoV-2 surveillance in schools: real-world evaluation of transmission control, testing resources, and educational disruption, **Elisabetta Colosi**

d. Characterisation of reporting interval for human cases of avian influenza A(H7N9), China, 2013–2017: a retrospective time-to-event analysis, **Chiamaka Jibuaku**

e. Risk Prioritisation of emerging infectious diseases for preparedness planning: The Belgian example, 2025-2026, **Clara Mazagatos**

f. Impact of Youth Jubilee 2025 on Emergency Department attendances in Rome: a controlled interrupted time series analysis using syndromic surveillance data, **Jasleen Singh**

g. After Action Review of the 2025 West Nile Virus Outbreak in the Lazio Region, Italy, **Ilaria Mussetto**

Poster tour 11

Surveillance and prevention of respiratory viruses

a. A fine-tuned foundation model for influenza forecasting across 78 countries, benchmarked against Italy's collaborative forecasting hub, **David Hauser**

b. Vaccine effectiveness against influenza A(H3N2) infection and hospitalization in recommended target groups over four seasons: A Spanish test-negative study using surveillance data from 2022/23 to 2025/26**, Gloria Pérez Gimeno**

c. Estimating the start of the influenza season using the Moving Epidemic Method (MEM) and GLM-based outbreak detection algorithms**, Matthew Hoyle**

d. Serological evidence of substantial Respiratory Syncytial Virus infection burden among older adults residing in Swedish long-term care facilities, **Preeti Moar**

e. Impact on RSV hospitalisations among infants in Sweden following the introduction of nirsevimab, season 2025-2026, **Rakel Brodin**

f. Temporal trends and sociodemographic predictors of maternal influenza vaccination in Region Stockholm: A register-based cohort study**, Hanna Josefsson**

g. Uncovering Human Metapneumovirus Burden of Disease through the Belgian Severe Acute Respiratory Infections Surveillance Network, **Peace Mpakaniye**

Poster tour 12

Burden and prevention of vaccine-preventable diseases

a. Evaluation of Nirsevimab effectiveness in preventing RSV infection in infants under one year during the first two RSV seasons following its introduction in primary and secondary care, **Annika Erdwiens**

b. Meningitis Outbreak in Kebbi State, Nigeria, 2025: Severe Mortality among Unvaccinated Children Highlights Urgent Need for Sub-National Diagnostic Capacity, **Munzali Zubairu**

c. Epidemiological profile and factors associated with death from meningococcal disease in the municipality of Belém, Pará State, northern Brazil, 2024–2025, **Camila Neves**

d. Coverage and timeliness for respiratory syncytial virus (RSV) immunisation and rotavirus vaccination in the National Immunisation Programme in the Netherlands, **Minke Holwerda**

e. Measles outbreak in an occupational setting in Spain: informing elimination strategies, **Esteban Aznar**

f. Rotavirus epidemiology in the Netherlands before implementation of rotavirus vaccination, 2014-2023, **Marije Bootsma**

g. RSV-related hospitalisations in infants averted by nirsevimab during the first implementation seasons in Spain and Portugal, **Sandra Campos Mena**

Poster tour 13

Data systems and surveillance

a. Nationwide epidemiology and machine learning-derived phenotypes of sepsis-associated delirium in Spain, 2017–2022, **Rosa María Cobo Zubia**

b. Data quality and reporting timeliness in Uzbekistan's infectious disease surveillance system: a baseline assessment for further strategical development, **Dariya Abzulinova**

c. From data to action: a regional epidemiological bulletin driving public health action in the Midlands region, England, **Melissa Harrison**

d. Completeness of laboratory surveillance for four bacterial meningitis pathogens in the Netherlands, 2015-2024, **Boas van der Putten**

e. Epidemiological trends in non-polio enterovirus infections in England, 2012–2025, **Tishya Venkatraman**

f. Extraordinary excess mortality detected by EuroMOMO during the severe heatwave affecting Europe in June-July 2026, **Sarah Kristine Nørgaard**

Poster tour 14

Surveillance and outbreak investigations of AMR

a. Prevalence of MRSA nasal colonisation in patients undergoing elective total joint arthroplasty: implications for targeted preoperative screening, **Nicola Sardi**

b. Investigating the effects of methodological de-duplication rules on routine bacterial antimicrobial resistance surveillance indicators in Germany 2023–2024, **Pontus Hedberg**

c. Consumption of antimicrobials relevant for multidrug-resistant infections in Piedmont, Italy, 2023–2024: regional trends and implications for antimicrobial stewardship, **Vanessa Imbriano**

d. Regional WGS surveillance identified a clinically relevant MDR Klebsiella pneumoniae ST15 cluster with possible intra-facility transmission, **Welmoed Silvis**

e. 30-day fatality of Klebsiella pneumoniae bloodstream infections in Emilia-Romagna, Italy, 2018-2025: a population-based study., **Davide Tarditi**

f. Prevalence of carbapenemase production in Enterobacterales with elevated imipenem MIC and low meropenem MIC in the Netherlands, **Rony Zoetigheid**

g. First reported outbreak of carbapenemase-producing Enterobacterales in a Belgian nursing home: investigation and management, **Hilde Vochten**

Poster tour 15

Artificial intelligence in public health

a. Scaling One Health Surveillance: AI-Driven Predictive Modeling of AMR Trends Using Municipal Wastewater in Pirkanmaa, Finland, **Saeed Ahmad**

b. Evaluating AI-assisted surveillance of healthcare-associated infections using a standard European point prevalence study in a regional hospital, the Czech Republic, 2025, **Jana Prattingerová**

c. Operationalizing LLM-based surveillance of healthcare-associated bloodstream infections: a data governance and de-identification framework, **Costanza Vicentini**

d. Artificial Intelligence for Healthcare-Associated Infection prediction in Adult Intensive Care Units: a systematic review of prognostic models, **Antonio Sciurti**

e. Are time series foundation models the new frontier for operational epidemic forecasting in Europe?, **Stefania Fiandrino**

f. All hype and no help? Assessing readiness for AI within a UK public health institute field epidemiology service, January 2026, **India Clancy**

g. Validation of locally deployed open-source LLMs for SARI detection in Spanish hospital records, **Susana Monge**

Poster tour 16

Late breakers (1)

a. Increasing Macrolide Resistance in Invasive Group A Streptococcal Infections: A Multiregional Surveillance Study in the Netherlands, **Thera Anne Mare Peeters**

b. Moderate end-of-season influenza vaccine effectiveness in 2025/26, but measurable protection against drifted A(H3N2) in Bavaria, Germany, **Eva Martschew**

c. Epidemiology of Viral Hepatitis B and C in Ukraine During Wartime: Incidence Trends and the Role of Expanded Screening, **Tetiana Koval**

d. Hand, foot, and mouth disease remains above pre-pandemic incidence in Catalonia, Spain: paediatric primary care surveillance through August 2026, **Víctor L. de Rioja**

e. Rapid late-summer resurgence in COVID-19 notifications with accelerated reinfections and a younger case profile, Castile and León, Spain, 2026, **Morella Pierina Tello Zapata**

f. The live shingles vaccine and primary care antimicrobial prescribing in the UK: A retrospective population-based cohort study, **Rebecca Walshe**

POSTER TOURS PROGRAMME *PROVISIONAL: last update 20 October 2026*

DAY 3 - *20 November: 14.15-15.15 (CET time zone)*

Poster tour 17

Surveillance of food- and water-borne diseases

a. Genomic surveillance for Salmonella spp. and Shigella spp. in Belgium in the era of multiplex PCR diagnostics, **Pauline Hinnekens**

b. Drivers of Rising Legionella Notifications in Southern Finland, 2020–2025: disentangling Diagnostic, Climatic, and Seasonal Influences, **Julia Jaeger**

c. Whole-Genome Sequencing (WGS) Uncovers Multiple Concurrent Salmonella Transmission Pathways and Recognizes Greater Disease Spread Overlooked by Conventional Surveillance, Moldova, 2025, **Irina Iaroslavtev**

d. Genomic surveillance of invasive non-typhoidal Salmonella (iNTS) in Belgium, 2014-2025: Hidden danger of uncommon serovars, **Julia Steger**

e. Advancing Legionella pneumophila genomic surveillance with a high-resolution cg/wgMLST schema for outbreak detection and investigation, **Vítor Borges**

f. Evaluation of the surveillance system for campylobacteriosis, Portugal, 2020-2024: timeliness and external completeness, **Joana Vidal-Castro**

g. Cryptosporidiosis reaches unprecedented levels in France during the summer of 2026: is climate warming playing a role?, **Damien Costa**

Poster tour 18

Surveillance of COVID-19 and influenza

a. Investigating post-pandemic regime shifts in influenza epidemiological patterns: a multinational analysis, **Styliani Evaggeli**

b. Factors associated with undertaking community respiratory testing amongst symptomatic FluSurvey participants in England, 2024-2025, **Jin-Min Yuan**

c. Influenza in Malta (2017–2025): Post-Pandemic Shifts in Incidence and Seasonality, **Norman Galea**

d. Severe Acute Respiratory Infection Surveillance in North Macedonia, 2023–2025: Risk Factors for RSV Infection, Influenza Infection and ICU admission in Children, **Enkela Pollozhani**

e. Wastewater-based surveillance for SARS-CoV-2 across six European countries: system heterogeneity, country use-cases and implications for comparison, **Niamh Tiernan**

f. Influenza-like illness defined by clinical diagnostic coding: Positive predictive value for influenza and COVID-19 post-pandemic, **Robert Norrie**

g. Comparison of Belgian COVID-19 mortality between epidemiological surveillance and death certificates for the years 2020, 2021 and 2022, **Serge Nganda**

Poster tour 19

Vaccine-preventable diseases: evidence to practice

a. Effectiveness of nirsevimab against hospitalisation with laboratory-confirmed respiratory syncytial virus in children aged <24 months, European multicentre study, September 2025—March 2026, **Lore Merdrignac**

b. Vaccine efficacy and safety of the adjuvanted herpes zoster subunit vaccine in immunocompromised adults aged 18-49 years: a systematic review to inform a German vaccination recommendation, **Sophie Hermanns**

c. Factors associated with absence of an identified epidemiological link among measles cases in an elimination setting: implications for case and contact investigation, Portugal, 2015-2025, **Raquel Eusébio**

d. Feasibility of a target trial emulation study to estimate vaccine effectiveness of the 2023 and 2024 autumn vaccine doses against hospitalisation due to COVID-19 in six EU/EEA countries: a VEBIS-EHR network study, **Alexandre Blake**

e. Determinants of vaccination intention in Romania: findings from Wave 2 of the People's Voice Survey using the 5Cs model of vaccination acceptance, **Bianca Enciu**

f. Impact of influenza vaccination in adults aged ≥65 years in Portugal: 2022/23-2024/25 seasons estimates, **Irina Kislaya**

g. Determinants of Mpox vaccine uptake in men who have sex with men and transgender persons during regular consultations at a Dutch Sexual Health Centre, **Joeri van Straalen**

Poster tour 20

Vector-borne diseases

a. Emerging vector-borne infectious disease risks: awareness gaps among Dutch travellers in Europe, **Iris Scholte**

b. Epidemiological Trends and Climatic Determinants of Human Leishmaniasis in Lazio Region, 2015–2025, **Francesco Vairo**

c. DENV-2 autochthonous transmission patterns in Italy: evidence from 2024 outbreaks, **Carla Molina Grané**

d. Clinical and epidemiological characteristics of West Nile Virus in Northern Cyprus: A retrospective case series (2019–2024), **Ertan Direnç**

e. Immunogenicity, clinical efficacy and safety of Malaria vaccines in children: a systematic review and meta-analysis, **Katsiaryna Bashlakova**

f. Autochthonous dengue outbreak in Tuscany, Italy: geographically dispersed cases linked to a common exposure site, August to September 2026, **Chiara Sacco**

Poster tour 21

Quantitative methods

a. Cost-effectiveness of MenB vaccination to control the spread of gonorrhoea in the UK, **Soeren Metelmann**

b. A hidden Markov model reveals environmental persistence and inter-department transfers as key drivers of drug-resistant Citrobacter spp. in a hospital, **Taeyong Lee**

c. Decrease in prevalence of sexually transmitted chlamydia infection among 15–29 years old individuals during 2009–2024 in Sweden: a mathematical modelling study, **Inga Velicko**

d. Closing the gap to cervical cancer elimination in Portugal: a modelling study, **Rita Tomaz**

e. Cost-Effectiveness and Uncertainty Analysis of Ebola Vaccination Strategies in Children and Adolescents, **Marianna Zarro**

f. Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact, **Mate Szilcz**

g. Optimal epidemic control: a nonlinear programming approach, **Sandra Montes-Olivas**

Poster tour 22

Social determinants of infectious diseases

a. Ethnic inequalities in respiratory virus epidemics in England: a mathematical modelling study, **Alexis Robert**

b. Barriers to mpox vaccination among rural residents in Manitoba and Alberta, Canada, **Mikayla Hunter**

c. Socioeconomic and demographic disparities in HPV awareness and cervical cancer prevention in rural Romania: findings from a large population-based survey, **Florina Ionete**

d. Screening and attitudes towards hepatitis C among marginalised populations in high- risk districts of southern Slovakia: results from 2024–2025, **Zuzana Jányová**

e. Correlates of Seroconversion among HIV-exposed Infants in Three High-burden Counties in Kenya, **Lucy Munyeki**

f. Epidemiological Analysis for Sexually Transmitted Infections in migrant population in Catalonia using multimodal healthcare data, **Nikolaos Karanikolaou**

Poster tour 23

Evidence to practice

a. Declining effectiveness of contact tracing during the emergence of the SARS-CoV-2 Omicron variant in Östergötland, Sweden, November 2021 – February 2022, **Kate Lillepold**

b. Systematic review of effectiveness of wide- spread population-based laboratory testing strategies during the COVID-19 pandemic, **Eeva Broberg**

c. Evaluating usage and impact of English AMR & HCAI surveillance outputs to inform future improvements, **Kathrin Loosli**

d. Sporadic community-acquired Legionnaires' disease by distance to cooling towers; To what extent does distance matter?, **Kevin Wassing**

e. The use of a multi-stream evidence synthesis to revise national Shiga toxin-producing Escherichia coli (STEC) infection guidelines on microbiological clearance in Norway, 2026 , **Liz Ertzeid Ødeskaug**

f. Mind the gap: Rebound of post-pandemic respiratory infections in children born during the COVID-19 pandemic, **Henrik Mellström Dahlgren**

g. Strengths, weaknesses, opportunities and threats (SWOT) of national surveillance systems for infectious diseases in Germany, **Paulina vom Felde genannt Imbusch**

Poster tour 24

Late breakers (2)

a. Epidemiological and Molecular Investigation of Enteroviral Meningitis in the West Midlands, England, 2026, **Georgia Davidson**

b. Monitoring of tendinitis and tendon rupture after ciprofloxacin use during the meningococcal B outbreak in Kent, 2026, **Julia Stowe**

c. Persistent environmental contamination in a food premises linked to two neonatal listeriosis cases in England, 2026, **Juliette Cavaye**

d. Cholera Outbreak Investigation in Borno State, Nigeria: Epidemiological Characteristics and Drivers of Transmission Among Cholera Cases, May–July 2026, **Lovisa Ntinda**

e. Severe Shiga toxin-producing Escherichia coli (STEC) outbreak among young children linked to a petting farm, Belgium, 2026, **Valeska Laisnez**

f. Time to population access for new immunisations across Europe: a 30-country analysis, **Anna Vicere**

g. From guidance to practice: contact management across European countries during an international Andes virus infection outbreak on a cruise ship, May-June 2026, **Esteban Aznar**